Crystal structure of dimethyl 2-((2 Z ,5 Z )-5-(2-methoxy-2-oxoethylidene)-2-{( E )-[2-methyl-5-(prop-1-en-2-yl)cyclohex-2-enylidene]hydrazinylidene}-4-oxothiazolidin-3-yl)fumarate

The crystal structure of the title compound, dimethyl 2-((2Z,5Z)-5-(2-meth­oxy-2-oxo­ethyl­idene)-2-{(E)-[2-methyl-5-(prop-1-en-2-yl)cyclo­hex-2-enyl­idene]hydrazinyl­idene}-4-oxo­thia­zolidin-3-yl)fumarate displays a conformational disorder which inverts the configuration of the chiral C atom within the cyclo­hexyl­idene ring.
The crystal structure and the conformation of the title compound, C22H27N3O7S, were determined from the synthetic pathway and by X-ray analysis. This compound is a new 4-thia­zolidinone derivative prepared and isolated as pure product from thio­semicarbazone carvone. The mol­ecule is built up from an oxo­thia­zolidine ring tetra­substituted by a meth­oxy–oxo­ethyl­idene, a maleate, an oxygen and a cyclo­hexyl­idene–hydrazone. The cyclo­hexyl­idene ring is statistically disordered over two positions, resulting in an inversion of configuration for the substituted carbon.